Clinical Policy: Belzutifan (Welireg)

Reference Number: CP.PHAR.553
Effective Date: 12.01.21
Last Review Date: 11.26
Line of Business: Commercial, HIM/ICHRA, Medicaid Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

Description

Belzutifan (Welireg®) is a hypoxia-inducible factor inhibitor.

FDA Approved Indication(s)

Welireg is indicated:

von Hippel-Lindau (VHL) disease

- For treatment of adult patients with VHL disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery

Renal cell carcinoma with a clear cell component (ccRCC)

- In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, for the adjuvant treatment of adult patients with ccRCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions
- In combination with lenvatinib, for the treatment of adult patients with advanced ccRCC following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor
- As monotherapy, for treatment of adult patients with advanced ccRCC following a PD-1 or PD-L1 inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI)

Pheochromocytoma or paraganglioma (PPGL)

- Adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or PPGL

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results, or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Welireg is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Von Hippel-Lindau Disease (must meet all)**:**

1. Diagnosis of VHL disease requiring therapy for associated RCC, CNS hemangioblastomas, or pNET, but not requiring immediate surgery;
2. Prescribed by or in consultation with an oncologist;
3. Age ≥ 18 years;

4. For Welireg requests, member must use belzutifan, if available, unless contraindicated or clinically significant adverse effects are experienced;
5. One of the following (a or b):
   a. Welireg is prescribed as single-agent therapy;
   b. For VHL-associated pNET: Welireg is prescribed concurrently with Sandostatin® LAR Depot (octreotide) or Somatuline® Depot (lanreotide);
6. Request meets one of the following (a or b):*
   a. Dose meets both of the following (i and ii):
      i. Dose does not exceed 120 mg (3 tablets) once daily;
      ii. Dose is at least 40 mg (1 tablet) once daily;
   b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration: 12 months

B. Renal Cell Carcinoma (must meet all)**:**

1. Diagnosis of ccRCC;
2. Prescribed by or in consultation with an oncologist;
3. Age ≥ 18 years;
4. Prescribed in one of the following ways (a, b, or c):
   a. As a single-agent, and both of the following (i and ii)
      i. Disease is advanced (unresectable, locally advanced, relapsed, or metastatic);
      ii. Member has previously received both of the following (1 and 2):
         1) PD-1 or PD-L1 inhibitor (*see Appendix B for examples*), unless provider submits documentation that member previously received a first-line regimen containing only a VEGF-TKI;
         2) VEGF-TKI (*see Appendix B for examples*);
   b. In combination with Keytruda® or Keytruda Qlex™ for adjuvant treatment, and one of the following (i, ii, or iii):
      i. Member is intermediate-high or high risk of recurrence following nephrectomy;
      ii. Following nephrectomy and resection of metastatic lesions;
      iii. For stage II with grade 4 tumors (most aggressive) or stage III disease, member has undergone stereotactic body radiation therapy (SBRT);
   c. In combination with Lenvima®, and both of the following (i and ii):
      i. Disease is advanced (locally advanced, relapsed, stage IV, or metastatic);
      ii. Member has previously received PD-1 or PD-L1 inhibitor (*see Appendix B for examples*);

**Prior authorization may be required for Keytruda, Keytruda Qlex, and Lenvima*

5. For Welireg requests, member must use belzutifan, if available, unless contraindicated or clinically significant adverse effects are experienced;
6. For adjuvant treatment of ccRCC, duration of therapy does not exceed 54 weeks;
7. Request meets one of the following (a or b):*
   a. Dose meets both of the following (i and ii):
      i. Dose does not exceed 120 mg (3 tablets) once daily;
      ii. Dose is at least 40 mg (1 tablet) once daily;

b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration: 12 months

C. Pheochromocytoma or Paraganglioma (must meet all)**:**

1. Diagnosis of PPGL;
2. Prescribed by or in consultation with an oncologist;
3. Age ≥ 12 years;
4. Disease is locally advanced, unresectable, or metastatic;
5. For Welireg requests, member must use belzutifan, if available, unless contraindicated or clinically significant adverse effects are experienced;
6. Welireg is prescribed as single-agent therapy;
7. Request meets one of the following (a or b):*
   a. Dose meets both of the following (i and ii):
      i. One of the following (1 or 2):
         1) Adults or pediatrics weighing ≥ 40 kg: Dose does not exceed 120 mg (3 tablets) once daily;
         2) Pediatrics weighing < 40 kg: Dose does not exceed 80 mg (2 tablets) once daily;
      ii. Dose is at least 40 mg (1 tablet) once daily;
   b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration: 12 months

D. Other diagnoses/indications (must meet 1 or 2)**:**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
   a. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
   b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. All Indications in Section I (must meet all)**:**

1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Welireg for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. For adjuvant treatment of ccRCC, duration of therapy does not exceed 54 weeks;
4. For Welireg requests, member must use belzutifan, if available, unless contraindicated or clinically significant adverse effects are experienced;
5. If request is for a dose increase, request meets one of the following (a or b):*
   a. New dose meets both of the following (i and ii):
      i. One of the following (1 or 2) (*note: pediatric dosing applies only for PPGL*):
         1) Adults or pediatrics weighing ≥ 40 kg: Dose does not exceed 120 mg (3 tablets) once daily;
         2) Pediatrics weighing < 40 kg: Dose does not exceed 80 mg (2 tablets) once daily;
      ii. Dose is at least 40 mg (1 tablet) once daily;
   b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2)**:**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
   a. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
   b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

ccRCC: RCC with a clear cell component
CNS: central nervous system
FDA: Food and Drug Administration
PD-1: programmed death receptor-1
PD-L1: programmed death ligand 1
pNET: pancreatic neuroendocrine tumors
PPGL: pheochromocytoma or paraganglioma
RCC: renal cell carcinoma
SBRT: stereotactic body radiation therapy
TKI: tyrosine kinase inhibitor
VEGF: vascular endothelial growth factor
VHL: von Hippel-Lindau

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Examples of PD-1 or PD-L1 inhibitors: Bavencio® (avelumab), Opdivo® (nivolumab), Keytruda® (pembrolizumab)	Varies	Varies
Examples of VEGF-TKIs: Inlyta® (axitinib), Cabometyx® (cabozantinib), Lenvima® (lenvatinib), Votrient® (pazopanib), sorafenib (Nexavar®), sunitinib (Sutent®), Fotivda® (tivozanib)	Varies	Varies

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): none reported
- Boxed warning(s): embryo-fetal toxicity

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
VHL disease, ccRCC	120 mg PO QD Until disease progression or unacceptable toxicity, or up to 54 weeks if for adjuvant treatment of ccRCC	120 mg/day
PPGL	Adults and pediatric patients weighing ≥ 40 kg: 120 mg PO QD Pediatric patients weighing < 40 kg: 80 mg PO QD Until disease progression or unacceptable toxicity	120 mg/day

VI. Product Availability

Tablet: 40 mg

VII. References

1. Welireg Prescribing Information. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; September 2026. Available at: https://www.welireg.com. Accessed October 12, 2026.
2. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: http://www.nccn.org/professionals/drug_compendium. Accessed October 13, 2026.
3. National Comprehensive Cancer Network. Kidney Cancer Version 2.2027. Available at: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed October 13, 2026.
4. National Comprehensive Cancer Network. Neuroendocrine and Adrenal Tumors Version 1.2026. Available at: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Accessed August 18, 2026.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
4Q 2022 annual review: no significant changes; references reviewed and updated. Template changes applied to other diagnoses/indications.	08.04.22	11.22
4Q 2023 annual review: added criterion for monotherapy per NCCN and NCH criteria; added maximum number of tablets corresponding to dose in initial and continued criteria; references reviewed and updated.	08.15.23	11.23
RT4: added new FDA-approved indication of advanced RCC.	12.20.23	
4Q 2024 annual review: added options for combination therapy for indication of VHL-associated pNET per NCCN Compendium; removed single-agent therapy criterion for continued therapy; references reviewed and updated.	07.15.24	11.24
RT4: for RCC, revised indication and criteria to specify clear cell histology per updated FDA labeling and NCCN, and added bypass of prior PD-1 or PD-L1 inhibitor therapy per NCCN.	04.30.25	
RT4: added new FDA-approved indication of PPGL; for all indications, revised continued approval duration to 12 months per standard approach.	05.21.25	
4Q 2025 annual review: revised initial approval durations for all indications to 12 months; references reviewed and updated.	07.07.25	11.25
RT4: added new FDA-approved indication for combination use for adjuvant treatment of patients with ccRCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.	06.22.26	
4Q 2026 annual review: no significant changes; added ICHRA line of business; references reviewed and updated. RT4: added indication for ccRCC in combination with Lenvima, following PD-1 or PD-L1 inhibitor; for ccRCC in combination with Keytruda or Keytruda Qlex as adjuvant treatment, added option for stage II or stage III disease and previous SBRT per NCCN.	10.13.26	11.26

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. "Health Plan" means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members

and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2021 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.